Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Massachusetts General Hospital Cancer Center

26 abstracts

Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.
Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.
Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
Phase II trial of pembrolizumab in patients with brain metastases.
Org: Massachusetts General Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, Yale University,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
Org: Weill Cornell Medical College - New York Presbyterian Hospital, Fox Chase Cancer Center, Arnie Charbonneau Cancer Institute, University of Calgary, Massachusetts General Hospital Cancer Center, Pfizer SLU,
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.
Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.
Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,
Abstract
Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.
Org: Massachusetts General Hospital Cancer Center, Northwestern Memorial Hospital, Chicago, IL, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Massachusetts General Hospital,
Abstract
Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer.
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, Emory University at Winship Cancer Institute, Clinical Care Options, LLC,
Abstract
Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.
Org: Faculdade de Medicina da Universidade de São Paulo, Massachusetts General Hospital Cancer Center, Federal University of Minas Gerais (UFMG), Case Western Reserve University School of Medicine, Penn State University College of Medicine,
Abstract
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).
Org: Guardant Health, Inc., Guardant Health, Sarah Cannon Research Institute/Tennessee Oncology, Winship Cancer Institute of Emory University, Massachusetts General Hospital Cancer Center,
Abstract
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy.
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Nectin-4 expression in primary breast cancer and associated clinical outcomes.
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Broad Institute of Harvard and MIT, Massachusetts General Hospital, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.
Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Winship Cancer Institute of Emory University, Seoul National University Hospital, IRCCS Ospedale San Raffaele,
Abstract
Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay.
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Emory University School of Medicine, Massachusetts General Hospital,
Abstract
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.
Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Evidera PPD, Bethesda, Bristol Myers Squibb,
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses.
Org: Roche Products Ltd., Genentech, Roche Products Limited, German Breast Group, Centre for Haematology and Oncology Bethanien,
Abstract
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.
Org: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Michigan, University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Hematology and Oncology,
Abstract
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
Org: Pfizer Inc., European Institute of Oncology IRCCS, National Cancer Center Hospital East, Kashiwa, Japan, Guangdong Lung Cancer Institute, Tennessee Oncology, PLLC,
Abstract
Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC-like disease subtype?
Org: Department of Medicine (DMED), University of Udine, Aviano, Italy, Washington University in St. Louis, St. Louis, MO, Universita degli Studi di Udine, Udine, Italy, Weill Cornell Medicine, New York, NY, Massachusetts General Hospital Cancer Center, Boston, MA,